Neumora Therapeutics
Clinical-stage biopharmaceutical company developing precision medicines for brain diseases, leveraging proprietary computational neuroscience platform to advance treatments for psychiatric and neurological disorders.
Notes
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with brain diseases. The company combines proprietary computational neuroscience, deep patient phenotyping, and clinical development to advance novel therapies for psychiatric and neurological disorders including major depressive disorder (MDD), generalized anxiety disorder (GAD), and other conditions.
Founded in 2019, Neumora went public on NASDAQ (ticker: NMRA) in 2023. The company was originally known as RBNC Therapeutics before rebranding to Neumora.
Team
- Paul L. Berns - Chief Executive Officer
- LinkedIn: linkedin.com/in/paulberns
- Joshua Pinto, Ph.D. - President
- Bill Aurora, Pharm.D. - Chief Operating & Development Officer
- Michael Milligan - Chief Financial Officer
- Nick Brandon, Ph.D. - Chief Scientific Officer
- Carol Suh - Chief Strategy Officer
- Jason Duncan - Chief Legal & Administrative Officer
- Lori Houle - Chief Technical Operations & Quality Officer
Additional Research Findings
- Listed on NASDAQ (NMRA) - IPO in September 2023
- Headquarters in Watertown, Massachusetts (Greater Boston area)
- Focus on major depressive disorder (MDD) and generalized anxiety disorder (GAD)
- Lead program: navacaprant (NMRA-140), a selective kappa opioid receptor antagonist for MDD
- Uses AI-driven computational neuroscience platform for drug development
- Backed by major investors including ARCH Venture Partners and Polaris Partners
- Originally founded as RBNC Therapeutics
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |